One Shot a Week: The Insulin That Could Change Everything for 100 Million Indians
Novo Nordisk just launched the world's first once-weekly insulin in a country with 100 million diabetics, and it's actually cheaper than the daily alternatives. India could be the ultimate test case for whether convenience can fix the global insulin adherence crisis.
365 Injections Down to 52
Imagine stabbing yourself with a needle every single morning before breakfast. Now imagine doing it once a week instead. That's the pitch behind Awiqli, Novo Nordisk's once-weekly insulin, which just launched in India. And in a country where more than 100 million adults have diabetes, the stakes are enormous.
Awiqli contains insulin icodec, the world's first and only basal insulin you take once a week instead of once a day. It's like switching from daily trips to the gas station to filling up every Sunday. Same fuel, way less hassle. The drug is already approved in the U.S., the EU, and 13 other countries, but India might be where it matters most.
Why India, Why Now
India isn't just a big diabetes market. It's the diabetes market. Roughly 101 million adults in the country have the disease, and the numbers keep climbing. Urban prevalence sits around 15–20%, with rural areas catching up fast.
But the scarier statistic isn't how many people have diabetes. It's how many aren't managing it. An estimated 43% of Indian diabetics don't even know they have the disease. Among those who do, only about 30% hit their blood sugar targets. More than half have dangerously poor control, with HbA1c levels (a key measure of long-term blood sugar) above 8%.
The reasons are painfully familiar: limited access to specialists, high out-of-pocket costs, low health literacy, and a healthcare system stretched thin, especially in rural areas. Daily insulin injections add another layer of friction. Many patients who should be on insulin delay starting it or skip doses because the daily burden feels overwhelming.
That's where a once-weekly shot becomes more than a convenience play. It becomes a potential game-changer for adherence.
The Price Tag Tells a Story
Novo Nordisk clearly learned from its GLP-1 pricing wars in India. Instead of launching Awiqli at a premium and slashing prices later (the playbook it used with Ozempic and Wegovy), the company came out swinging with aggressive pricing from day one.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
A typical weekly dose of 70 units costs about ₹261 per week, which works out to roughly ₹50 per day or about $2.70 per week. That's not just affordable by branded insulin standards; it's actually 30–40% cheaper per unit than many existing daily basal insulins, which typically run ₹345 to ₹453 for the same 70-unit equivalent.
Read that again. The newer, more convenient product is cheaper than the older, less convenient alternatives. That almost never happens in pharma. Novo is betting that low pricing plus genuine convenience will drive massive adoption in a market where penny-pinching isn't optional; it's survival.
The drug comes in pre-filled FlexTouch pens: a 700-unit pen (lasting about 10 weeks) for ₹2,611 and a 2,100-unit pen for ₹7,833. Both are available through a national distribution network of roughly 4,500 distributors.
What the Clinical Data Actually Shows
Awiqli's approval rests on the ONWARDS clinical trial program, six Phase 3 studies comparing once-weekly icodec against daily basal insulins like glargine and degludec. The results were solid, if not spectacular.
In type 2 diabetes (which accounts for the vast majority of cases in India), Awiqli was non-inferior to daily insulin across all trials and actually showed statistically superior blood sugar reduction in most studies with insulin-naïve patients. In the flagship ONWARDS 1 trial, patients on weekly icodec saw an HbA1c treatment difference of about −0.19 percentage points better than daily glargine at 52 weeks. Not a revolution, but a meaningful edge.
Time in range (the percentage of the day patients spend at healthy blood sugar levels) also favored Awiqli in type 2 diabetes trials. And importantly, hypoglycemia rates (dangerous blood sugar drops) were similar to or lower than daily insulin in most type 2 studies.
The type 1 diabetes story is less rosy. Patients with type 1 diabetes on Awiqli experienced more hypoglycemic episodes than those on daily degludec, particularly on days 2 through 4 after injection, when the drug hits peak levels. Regulators flagged this as a less favorable profile, though HbA1c was still non-inferior. In India, where type 2 dominates, this limitation matters less, but it's worth noting.
Novo's Bigger Chess Game
This launch isn't happening in a vacuum. Novo Nordisk is in the middle of a sweeping strategic overhaul of its India business.
The company is discontinuing Mixtard in Penfill and FlexPen formats, while Mixtard 40 IU vials will continue to be available in India, to push prescribers toward higher-value products like GLP-1 drugs (semaglutide) and now once-weekly insulin. Think of it as upgrading from a flip phone to a smartphone: the old product works fine, but Novo wants everyone on the new platform.
At the same time, Novo faces brutal competition. Indian generic drugmakers have launched semaglutide copies at discounts of 50–80% below Novo's original prices. Eli Lilly got into the GLP-1 market in India early and grabbed first-mover advantage. Sanofi's daily basal insulins like Lantus and Toujeo remain entrenched.
Novo's response is a dual strategy: launch premium innovations like Awiqli at surprisingly competitive prices, while partnering with Indian companies for authorized generics to cover the mass market. The company's India leadership has described the goal as reaching "Indians in every corner of the country."
The Adherence Problem No One Talks About
For all the excitement about once-weekly dosing, the bigger question is whether convenience alone can move the needle in a country where a large proportion of diabetics aren't on any medication at all.
Awiqli solves the injection burden problem. It doesn't solve the diagnosis gap, the specialist shortage, the health literacy deficit, or the rural infrastructure challenges that keep tens of millions of Indians from getting basic diabetes care. You can build the world's best insulin pen, but it doesn't help if patients never see a doctor in the first place.
Still, for the subset of patients who are diagnosed and do have access to prescribers, fewer injections could make a real difference. Reducing the frequency from daily to weekly removes one of the most common reasons patients resist or abandon insulin therapy: needle fatigue.
The Bottom Line
Awiqli's India launch is a commercial milestone with genuine public health implications. A once-weekly insulin that's cheaper than daily alternatives, available through 4,500 distributors, and backed by strong Phase 3 data? That's a compelling package for a country drowning in uncontrolled diabetes.
But this isn't a silver bullet. The real test isn't whether Awiqli works (the trials already proved that). It's whether Novo Nordisk can get it into the hands of patients who need it most, in a market where the biggest barriers aren't pharmacological; they're structural. If Novo cracks that code, India won't just be another market. It'll be the proof of concept for deploying next-generation insulin across every emerging economy on the planet.
Deals & M&A
5 min read
The $929M Bet on a Drug That Already Failed Twice
Zymeworks is spending $929 million to buy Theravance Biopharma, a company whose lead drug failed twice in late-stage trials. The real prize isn't the drug; it's a portfolio of royalty cash flows that reveals where biotech M&A is really headed.
